FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid ...
Eagle-Tribune7h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vertex gets FDA approval for non-opioid pain reliever
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) rose 3% in post-market trading Thursday on news the company had received FDA ...
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025
We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...
Axsome gets FDA approval for Symbravo for migraine
Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or ...
10 Best ASX Stocks to Buy According to Hedge Funds
According to a report by the Australian Bureau of Statistics (ABS) published on December 4, 2024, the Australian economy grew ...
Hosted on MSN12h
Is Tonix Pharmaceuticals the Next Biotech Breakout?
Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...
Clene Inc. secures additional NIH grant funds for ALS therapy
Salt Lake City-based pharmaceutical company Clene Inc. has amended its grant subaward with Columbia University, securing up ...
manilatimes10h
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company”), a pharmaceutical company focused on developing new ...
First New Non-Opioid Painkiller in Decades Gets FDA Approval
Vertex Pharmaceuticals won U.S. approval for the first new non-opioid painkiller in decades, which could be a blockbuster if the company can persuade insurers and doctors to embrace the non-addictive ...
Chimerix stock soars to 52-week high, hits $4.22
Chimerix Inc (NASDAQ: NASDAQ:CMRX) stock has reached a new 52-week high, touching $4.22 in recent trading, giving the company a market capitalization of $375 million. According to InvestingPro data, ...
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial ...